Appraising the Use of JAK Inhibitors in Treating Myelofibrosis

Cancer research · Myelofibrosis

JAK inhibitors have been the mainstay treatment for patients who have been diagnosed with myelofibrosis.

Evidence level: Állatkísérletes. Állatmodellben vizsgálták.

Original source

Related signals

• ASH 2024: New Research, Data Drive Progress in Myelofibrosis
• Primary Myelofibrosis
• Extended Access of Momelotinib in Adults With Myelofibrosis
• The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non‑JAK Inhibitor Therapies
• Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis